Literature DB >> 11016651

Use of two predictive algorithms of the world wide web for the identification of tumor-reactive T-cell epitopes.

J Lu1, E Celis.   

Abstract

Tumor cells can be effectively recognized and eliminated by CTLs. One approach for the development of CTL-based cancer immunotherapy for solid tumors requires the use of the appropriate immunogenic peptide epitopes that are derived from defined tumor-associated antigens. Because CTL peptide epitopes are restricted to specific MHC alleles, to design immune therapies for the general population it is necessary to identify epitopes for the most commonly found human MHC alleles. The identification of such epitopes has been based on MHC-peptide-binding assays that are costly and labor-intensive. We report here the use of two computer-based prediction algorithms, which are readily available in the public domain (Internet), to identify HL4-B7-restricted CTL epitopes for carcinoembryonic antigen (CEA). These algorithms identified three candidate peptides that we studied for their capacity to induce CTL responses in vitro using lymphocytes from HLA-B7+ normal blood donors. The results show that one of these peptides, CEA9(632) (IPQQHTQVL) was efficient in the induction of primary CTL responses when dendritic cells were used as antigen-presenting cells. These CTLs were efficient in killing tumor cells that express HLA-B7 and produce CEA. The identification of this HLA-B7-restricted CTL epitope will be useful for the design of ethnically unbiased, widely applicable immunotherapies for common solid epithelial tumors expressing CEA. Moreover, our strategy of identifying MHC class I-restricted CTL epitopes without the need of peptide/HLA-binding assays provides a convenient and cost-saving alternative approach to previous methods.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11016651

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas.

Authors:  An-hua Wu; Jing Xiao; Lars Anker; Walter A Hall; Dale S Gregerson; Webster K Cavenee; Wei Chen; Walter C Low
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 2.  Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept.

Authors:  Megan M O'Meara; Mary L Disis
Journal:  OMICS       Date:  2011-07-06

3.  Lack of effective T-lymphocyte response to the PAX3/FKHR translocation area in alveolar rhabdomyosarcoma.

Authors:  David A Rodeberg; Rebecca A Nuss; Carrie J Heppelmann; Esteban Celis
Journal:  Cancer Immunol Immunother       Date:  2004-11-20       Impact factor: 6.968

4.  Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice.

Authors:  Agnieszka Boesen; Krishnan Sundar; Richard Coico
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

5.  Recognition of six-transmembrane epithelial antigen of the prostate-expressing tumor cells by peptide antigen-induced cytotoxic T lymphocytes.

Authors:  David A Rodeberg; Rebecca A Nuss; Sherine F Elsawa; Esteban Celis
Journal:  Clin Cancer Res       Date:  2005-06-15       Impact factor: 12.531

6.  Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells.

Authors:  Sid P Kerkar; Dhanalakshmi Chinnasamy; Neima Hadi; Jan Melenhorst; Pawel Muranski; Alexandros Spyridonidis; Sawa Ito; Gerrit Weber; Fang Yin; Nancy Hensel; Ena Wang; Francesco M Marincola; Austin John Barrett
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

Review 7.  Can we predict mutant neoepitopes in human cancers for patient-specific vaccine therapy?

Authors:  Eric R Lutz; Elizabeth M Jaffee
Journal:  Cancer Immunol Res       Date:  2014-05-02       Impact factor: 11.151

Review 8.  Future directions in cancer prevention.

Authors:  Asad Umar; Barbara K Dunn; Peter Greenwald
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

Review 9.  PDEF and PDEF-induced proteins as candidate tumor antigens for T cell and antibody-mediated immunotherapy of breast cancer.

Authors:  Ashwani K Sood
Journal:  Immunol Res       Date:  2010-03       Impact factor: 2.829

Review 10.  Peptide epitope identification for tumor-reactive CD4 T cells.

Authors:  Hiroya Kobayashi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2008-05-20       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.